Back to Top
Ibritumomab Biosimilar - Research Grade
$315.00 - $19,890.00
Ibritumomab Biosimilar - Research Grade
Endotoxin
≤ 1.0 EU/mg as determined by the LAL method
Purity
>95% by SDS-PAGE
Species Reactivity
Human
Target
CD20
Concentration
5mg/ml
Isotype
Human IgG1 (P192T/R193W/K227M/S325R/N399D/N401D)-kappa
Host
CHO Cells
Sequence
https://www.imgt.org/mAb-DB/
Buffer
ICH3002
Uniprot
P11836
Shipping Conditions
Blue ice
Background
CD20 is a B-lymphocyte surface antigen involved in B-cell activation and a well-established target across B-cell malignancy and autoimmunity research. This anti-human CD20 recombinant monoclonal antibody is an unconjugated, non-therapeutic analog of ibritumomab, supplied for research use only. Produced to rigorous in vivo standards and purified to low endotoxin, it is manufactured in scalable milligram (mg) to gram (g) quantities to serve bulk and high-throughput laboratories. The reagent is appropriate for B-cell binding and depletion assays, in vitro functional screening, ADCC and CDC investigations, and in vivo oncology and immunology models.
Other Names
MS4A1, B1, Bp35, CD20, CVID5, LEU-16, MS4A2, S7, membrane spanning 4-domains A1, FMC7
Specificity
Detects human CD20
Purification Method
This monoclonal antibody was purified using Protein A
Formulation
Sterile, preservative-free, solution in PBS. BSA and Azide free.
Storage
This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.
Applications
Functional Assays
Application Notes
This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.
Use
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Write Your Own Review













